William A Seeds

Title : Advanced course: GLP-1 agonists - The future of diabetes research and clinical treatments

Abstract:

Heart disease remains the number leading cause of death year after year. The increased risk factors are certainly related to cardiovascular conditions but are also significantly attributable to metabolic disease states.

There are significant advances in cardiovascular interventions, but the metabolic and autoimmune side is only just beginning.

Statins are and have been the most popular intervention for high cholesterol and other lipids. If we look closely at the lipoproteins that are affected by statins, there are two in particular that stand out: the APO-A and APO-B lipoproteins. These lipoproteins can completely change the way we’re translating important biomarkers such as: cholesterol, triglycerides, HDL’s and LDL’s. These key lipoproteins are made in the enterocyte of the colon and synthesized in the liver. If this isn’t supported by a healthy microbiome and balanced immune system, it’s clear to see how cardiac issues can arise from these disease states.

The key to a healthy heart is through the microbiome and the immune system. Diet and exercise are mandatory treatments to add to the protocol, but what is the intervention to prevent future degradation? In this advanced course, we will uncover how GLP-1 Agonists will be to the future of treating cardiovascular disease– through the microbiome and immune systems. We will also explore how GLP-1 Agonists will be the future of care for Diabetes and other metabolic diseases.

Audience Take Away:

• How metabolic and autoimmune diseases contribute to the number one leading cause of death - cardiovascular disease.
• What are GLP-1 Agonists and how do they work in the microbiome
• How GLP-1 Agonists compare to other popular drugs such as Metformin, Statins, and other popular pharmaceuticals.
• This will assist practitioners’ diabetes patients and help them lose and maintain a healthy weight.
• Absolutely, More is being written in medical literation regarding GLP-1 Agonists in all of its pleotropic effects in changing dementia and Alzheimer’s, and other neurological conditions.
• It helps the practitioners care of their patients by understanding the clinical protocol.

Biography:

Dr. Seeds is a board-certified orthopedic surgeon practicing medicine for over 27 years, and the Founder and Medical Director of the Seeds Scientific Research & Performance Mastermind. He is Chief of Surgery and Orthopedic Residency Site Director for University Hospital, Conneaut & Geneva, OH. He has been honored at the NFL Hall of Fame for his medical expertise and in treating professional athletes, and serves as Professional Medical Consultant for the NHL, MLB, NBA, and NBC’s Dancing With The Stars. Dr. Seeds is also a medical researcher, and continues to write and publish on the NIH and other medical journals. He is also the author of Peptide Protocols Vol.1, the world’s first handbook about peptides written for practitioners. Today at the Seeds Scientific Research and Performance Institute, he is dedicated to bringing Cellular Medicine and the study of Epigenome to the forefront of the medical community through research, training, and improved patient outcomes. His practice is at the Olympic training facility: Spire Institute Geneva, OH; and at the Redox Medical Group, Beverly Hills, CA.